Five RCTs recently published in mainstream scientific journals that confirm major, statistically significant benefits of ivermectin against COVID-19 as reported in several prior RCTs
Major benefits of ivermectin (IVM) treatment for COVID-19 have been known since the results of 20 such randomized controlled trials (RCTs) were reported, as compiled in January 2021. Of the eight of these RCTs that tracked mortality or morbidity in patients with serious cases, seven showed statistically significant clinical improvements. The pooled mortality reduction in these eight RCTs was 78% in the treatment vs. controls groups, and the RCT that used the highest dose of IVM reported a 92% reduction in mortality (p < 0.001). Three RCTs for IVM prevention of COVID-19 and two animal studies of IVM at low human-equivalent doses likewise reported pronounced efficacy. Here we note the recent publication of RCTs for IVM treatment or prevention of COVID-19 in mainstream scientific journals that confirm these previously reported findings.
The consistently observed, major benefits of ivermectin (IVM) for COVID-19 treatment have been known since a January 2021 meta-study compiled results of 20 such randomized clinical trials (RCTs).1 Of the eight of these RCTs that tracked mortality or morbidity in patients with moderate or severe symptoms (4 double-blind,2-5 1 single-blind,6 and 3 non-blinded7-9), seven showed statistically significant clinical improvements (all but Podder et al.8). The pooled mortality reduction in these eight RCTs for the IVM treatment group vs. controls was 78% (mortality of 2.1% for IVM, 9.5% for controls). The RCT that used the highest dose of IVM, 1,600 μg/kg total, had 2 vs. 24 deaths in the treatment vs. control group (n=200 each),7 a 92% reduction in mortality (p < 0.001).
